Lung Cancer Clinical Trials
CRB-701
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an
Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors
AB598
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
GEN1042
A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors
COPERNICUS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in a combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab Combination with Platinum-Based Chemotherapy as Second-line Treatment, EGFR-Mutated Locally Advanced or Metastatic NSCLC.
TEMPUS GEMINI NSCLC STUDY
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
Pfizer C5751003
An Open-Label, Randomized, Controlled Phase 3 Study Of Sigvotatug Vedotin In Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy As First-Line Treatment In Participants With Pd-L1 High (≥50% Of Tumor Cells Expressing Pd-L1), Locally Advanced, Unresectable, Or Metastatic Non-Small Cell Lung Cancer (Be6a Lung-02)
Gilead
A Global, Multicenter, Randomized, Open-label, Phase 3 study of Sacituzumab Govitecan versus Standard of Care (SoC) in Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC).
COCOON
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
FULL TITLE
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Budigalimab in Advanced or Metastatic Non- Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536)